Clinical Trial Update: Urodynamic Effects of UK-369,003 in Men With Lower Urinary Tract Symptoms [Phase 2]

View source ↗

Summary

Phase 2 study assessing urodynamic effects of UK-369,003 in men with lower urinary tract symptoms due to benign prostatic hyperplasia; the trial is completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Benign Prostatic Hyperplasia

Drugs mentioned

• UK-369,003 (UK-369,003)

Snippet

Sponsor: Pfizer | Conditions: Prostatic Hyperplasia | Phase 2 | Status: COMPLETED